Epidemiological, therapeutic, cytogenetic, and molecular profile of chronic myeloid leukemia at the national reference university hospital of N’Djamena from 2010-2020, Chad

Djimadoum Mbanga 1, 2, Bessimbaye Nadlaou 1, 2, *, Issakou Bakarnga-Via 2, Josué Mbairané 2, Choua Ouchemi 2, Abdelsalam Tidjani 2 and Avocksouma Djona Atchenemou 2

1 Laboratory Hematology Unit of the National Reference University Hospital (CHU-RN) of N’Djamena, BP 130 N’Djamena, Chad.
2 Faculty of Human Health Sciences (FSSH), University of N’Djamena, BP 1117 N’Djamena, Chad.
 
Research Article
World Journal of Advanced Research and Reviews, 2021, 10(03), 127–140
Article DOI: 10.30574/wjarr.2021.10.3.0269
 
Publication history: 
Received on 03 May 2021; revised on 06 June 2021; accepted on 08 June 2021
 
Abstract: 
The aim is to determine the epidemiological and cytogenetic profile (Philadelphia chromosome: Ph1) and the bcr-abl gene in patients with chronic myeloid leukemia (CML) and to assess the therapeutic response of patients to hydroxy-urea and Imatinib treatment. From January 1, 2010 to December 30, 2020, an observational study for diagnostic and analytical purposes was carried out in 54 cases of CML at the National Reference University Hospital (CHU-RN) of N’Djamena. All selected patients presented with splenomegaly on physical examination.
Significant differences were observed between the proportion of housewives (31.48%) and civil servants (3.70%), emaciated patients (27.84%) and those with fever (3.70%) with the probabilities of 0.001 and 0.001 respectively. Hyperleukocytosis ranged from 100,000-149,000 GB / mm3 (42.30%) and the platelet count ranged from 20,000 / mm3 to 611,000 / mm3. Polymorphic and massive myeloma was 30-80% of cases, a medullary karyotype with 33.33% Ph1 + chromosome and 66.66% Ph1-, 33.33% bcr-abl transcript and 33.33% transcribed b3 a2 respectively.
The treatment regimens were: Hydroxy-Urea (HU) + prednisolone (60%), and Imatinib + prednisolone (40%). Partial hematological remission was obtained in 40% of cases. CML is a condition that occurs at all ages and especially in men in our region. The continuation of this study at the national level will allow the public authorities to achieve national prevalence and to organize effective prevention and early management.
 
Keywords: 
Chronic myeloid leukemia; Epidemiology; Clinic; cytogenetic; Molecular; Chad
 
Full text article in PDF: 
Share this